Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91.
DB-67 and its lactone homolog DB-91 are derivatives of topoisomerase I inhibitor camptothecin (CPT) with silyl moiety, which may exhibit a slower inactivation process by changed kinetics of protein binding and/or hydrolysis of its lactone ring and result in increased antitumor activity and decreased toxicity. Pharmacokinetic properties and antitumor activities of the two silatecans were studied and compared. The lactone ring of DB-91 is more stable than those of all the other CPT derivatives in mouse plasma. Both silatecans were metabolized faster than CPT in mouse and human liver microsomes. Pharmacokinetic study revealed a plasma elimination half-life (t(1/2)) of 33 and 94min for DB-67 and DB-91, respectively; similar systemic exposure in plasma between DB-67 and DB-91; and similar volume of distribution at the steady state between DB-67 and DB-91, approximately 15-fold smaller than that of CPT. While DB-91 showed limited activities, DB-67 exhibited activities against the growth of in vivo-like histocultured human tumors and s.c. xenografted human tumors in nude mice. In conclusion, DB-67 is more effective, compared to DB-91, against human tumor growth in in vitro, in vivo-like and in vivo systems. Further pre-clinical and clinical investigations of DB-67 are warranted.
Yeh
Teng-Kuang
TK
Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.
Li
Chien-Ming
CM
Chen
Ching-Ping
CP
Chuu
Jiuun-Jye
JJ
Huang
Chen-Lung
CL
Wang
Hsin-Sheng
HS
Shen
Chien-Chang
CC
Lee
Tien-Yi
TY
Chang
Chi-Yen
CY
Chang
Chung-Ming
CM
Chao
Yu-Sheng
YS
Lin
Chin-Tarng
CT
Chang
Jang-Yang
JY
Chen
Chiung-Tong
CT
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D019008:Drug Resistance, Neoplasm; D004355:Drug Stability; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008862:Microsomes, Liver / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D017646:Organosilicon Compounds / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D013997:Time Factors; D059004:Topoisomerase I Inhibitors; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
C548684:7-tert-butyldimethylsilyl-10-hydroxyhomocamptothecin; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D017646:Organosilicon Compounds; D059004:Topoisomerase I Inhibitors; C415575:7-tert-butyldimethylsilyl-10-hydroxycamptothecin; D002166:Camptothecin